摘要
This study investigated the efficiency of natural killer(NK)cell immunotherapy on non-small cell lung cancer with and without EGFRmutations in order to evaluate the response rate(RR)and progression-free survival(PFS).Among the 48 patients recruited,24 were clinically confirmed to be EGFR mutation positive.The study group was treated with autologous NK cell immunotherapy.Comparisons of the lymphocyte number,serum tumourrelated biomarkers,circulating tumour cells(CTC),Karnofsky Performance Status(KPS)and survival curves were carried out before and after NK cell immunotherapy.The safety and short-term effects were evaluated,followed by median PFS and RR assessments.The serum CEA and CA125 values were found lower in the NK cell therapy group than that of the non-NK treatment group(p<0.05).Theχ2 test showed a 75%RR of the study group A,significantly higher than that of the control group B(16.7%;p<0.01).The RR of groups C(58.3%)and D(41.7%)were not statistically significant.The p values of the 4 groups were 0.012,0.012,0.166 and 1 from group A to group D,respectively.The median PFS was 9 months in EGFR mutation positive group undergoing NK cell infusion interference.By evaluating the changes in immune function,tumour biomarkers,CTC,KPS and PFS,we demonstrated that NK cell therapy had better clinical therapeutic effects on EGFR mutation-positive lung adenocarcinoma.
基金
The authors thank all 48 participants.This study was funded by the Innovation of Science and Technology Commission of Shenzhen(Grant No:KQJSCX2017033116-0008397,JCYJ20170412155231633,JCYJ20170307171034705 and JCYJ20170816105345191).
